Since 2013, Dr. Brantley has developed expertise in Clinical and Non-Clinical Pharmacology, Pharmacokinetics, Pharmacometrics and Scientific Writing. Dr. Brantley’s focus is mostly in early phase Oncology and Antiviral programs. Dr. Brantley has worked on approximately 6 approved drugs, 3 NDAs, 5 INDs, 60+ PK and Population PK analyses.
Education